TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01907321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Measures performed on all subjects
Description: Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary function test
Description: Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
Study: NCT03170882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study: NCT03243006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 2 tablets of 500mg of paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol/Paracetamol combination
Description: 2 tablets of tramadol/paracetamol combination (32.5mg/325mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2 tablets of placebo
Study: NCT01907321

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary function test
Description: Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluoroscopic swallow study
Description: Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
Study: NCT02808182

Intervention type: OTHER
Group type: OTHER
Intervention: liquid meal
Description: At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
Study: NCT01201772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg, 30mg, or 60mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg, 30mg, or 60mg
Study: NCT03042741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atherosclerosis vaccine
Description: Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
Study: NCT01907321

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Fluoroscopic swallow study
Description: Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
Study: NCT04300361

Intervention type: GENETIC
Intervention: Sequencing of DPYD gene
Description: The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
Study: NCT02637414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flourishing App Program
Description: This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
Study: NCT03539211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotation Exercises
Description: The subjects received 7 trunk rotation stability exercises x 10 reps each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Exercises
Description: The subjects received 7 traditional exercises x 10 reps each
Study: NCT03042741

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Half of the patients will be randomly assigned to receive placebo pill
Study: NCT04466137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF
Description: YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhG-CSF
Description: YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
Study: NCT04046445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP128
Description: 5-6 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: ≥ 7 IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: ≥ 7 IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: ≥ 7 IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: ≥ 7 IV infusions
Study: NCT00812409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation with exercise
Description: Whey protein supplementation with resistance and aerobic exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation with exercise
Description: Whey protein supplementation with resistance and aerobic exercise.
Study: NCT04046445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: ≥ 7 IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: ≥ 7 IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: ≥ 7 IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSV-GP128
Description: 1 single IV injection
Study: NCT00812409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation with exercise
Description: Whey protein supplementation with resistance and aerobic exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non protein supplementation with exercise (control)
Description: Non protein supplementation with resistance and aerobic exercise.
Study: NCT04466137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF/PEG-rhG-CSF
Description: rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
Study: NCT01543893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video instruction
Description: Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal instruction
Description: Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm
Study: NCT02178852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRIGEMINAL NERVE STIMULATION (TNS)
Description: TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
Study: NCT01329653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training
Description: 12 weeks of aerobic training, 4X/week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait list
Description: wait list control condition
Study: NCT02247011

Intervention type: OTHER
Group type: OTHER
Intervention: Questionaire survey
Description: We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionaire survey
Description: We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.

Intervention type: RADIATION
Group type: OTHER
Intervention: Bone mineral density examination
Description: We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.

Intervention type: RADIATION
Group type: OTHER
Intervention: Bone mineral density examination
Description: We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.

Intervention type: RADIATION
Group type: OTHER
Intervention: Vertebral fracture assessment
Description: X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.

Intervention type: RADIATION
Group type: OTHER
Intervention: Vertebral fracture assessment
Description: X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.

Intervention type: OTHER
Group type: OTHER
Intervention: Biochemical markers analysis
Description: Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).

Intervention type: OTHER
Group type: OTHER
Intervention: Biochemical markers analysis
Description: Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
Study: NCT01207076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-AHN-12
Description: The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy.
Study: NCT02965742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratos
Description: A machine made by DMS group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratos
Description: A machine made by DMS group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hologic QDR 4500A
Description: A machine made by Hologic inc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hologic QDR 4500A
Description: A machine made by Hologic inc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hologic HORIZON A
Description: A machine made by Hologic inc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hologic HORIZON A
Description: A machine made by Hologic inc.
Study: NCT01532284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polar Body Biopsy
Description: PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
Study: NCT03170115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
Study: NCT03684603

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: melody during motor training and slow wave sleep
Description: sequence of tones which are presented to the patient using earphones

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: melody only during motor training
Description: sequence of tones which are presented to the patient using earphones
Study: NCT00753103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Daily oral 1mg/kg tapered over 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Daily oral 1mg/kg tapered over 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchange
Description: Additional therapy for patients with severe vasculitis (creatinine \> 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 500 mg intravenous infusion daily for three days at lead physicians discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 500 mg intravenous infusion daily for three days at lead physicians discretion.
Study: NCT02091752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
Study: NCT03938337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 Not Previously Treated
Description: Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 Treated Previously
Description: Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
Study: NCT00729209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study: NCT04777383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Iontophoretic administration of 5 different concentrations of acetylcholine
Study: NCT02731677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
Study: NCT02609841

Intervention type: DEVICE
Intervention: Cardiac rhythm remote monitoring system
Description: Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
Study: NCT03227653

Intervention type: DRUG
Intervention: Efavirenz
Description: Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS

Intervention type: DRUG
Intervention: Nevirapine
Description: Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS

Intervention type: DRUG
Intervention: Lopinavir-Ritonavir Drug Combination
Description: Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
Study: NCT04486430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL
Description: 1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL
Description: 1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL
Description: 1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
Study: NCT01944098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03702348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
Study: NCT01639339

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Placebo plus standard therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg plus standard therapy
Description: Belimumab 10 mg/kg plus standard therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy
Study: NCT01738607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Gum acacia dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose
Description: dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04062214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT-PM
Description: SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.